Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Public ClinicalTrials.gov record NCT06918431. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study Evaluating the Safety and Efficacy of Asparaginase Erwinia Chrysanthemi- Recombinant-Rywn (Recombinant Erwinia Asparaginase) During Pediatric-Inspired Regimen in High-Risk Adults With Newly Diagnosed ALL or LBL
Study identification
- NCT ID
- NCT06918431
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- City of Hope Medical Center
- Other
- Enrollment
- 53 participants
Conditions and interventions
Interventions
- Asparaginase Erwinia chrysanthemi Drug
- Biospecimen Collection Procedure
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
- Computed Tomography Procedure
- Cyclophosphamide Drug
- Cytarabine Drug
- Daunorubicin Hydrochloride Drug
- Dexamethasone Drug
- Echocardiography Procedure
- Lumbar Puncture Procedure
- Mercaptopurine Drug
- Methotrexate Drug
- Positron Emission Tomography Procedure
- Rituximab Biological
- Vincristine Sulfate Drug
Drug · Procedure · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 54 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 9, 2025
- Primary completion
- Mar 29, 2029
- Completion
- Mar 29, 2029
- Last update posted
- Mar 16, 2026
2025 – 2029
United States locations
- U.S. sites
- 8
- U.S. states
- 5
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope at Phoenix | Phoenix | Arizona | 85338 | Recruiting |
| City of Hope Medical Center | Duarte | California | 91010 | Recruiting |
| City of Hope at Irvine Lennar | Irvine | California | 92618 | Not yet recruiting |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | Not yet recruiting |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | Not yet recruiting |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | Not yet recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Not yet recruiting |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06918431, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06918431 live on ClinicalTrials.gov.